From: Cancer risk in immune-mediated inflammatory diseases (IMID)
Biologic | Type of molecule | IMIDs for which it is licensed |
---|---|---|
Infliximab (Remicade®) | Chimeric monoclonal antibody against TNF | RA, psoriatic arthritis, ankylosing spondylitis, ulcerative colitis, Crohn’s disease, plaque psoriasis |
Adalimumab (Humira®) | Human monoclonal antibody against TNF | RA, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis, plaque psoriasis, polyarticular juvenile idiopathic arthritis |
Golimumab (Simponi®) | Human monoclonal antibody against TNF | RA, psoriatic arthritis, ankylosing spondylitis |
Certolizumab pegol (Cimzia®) | Pegylated humanized Fab’ monoclonal antibody fragment against TNF | RA, Crohn’s disease |
Etanercept (Enbrel®) | Fusion protein of two TNF receptor 2 extracellular domains and the Fc portion of human IgG | RA, polyarticular juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, plaque psoriasis |
Tocilizumab (Actemra® or RoActemra®) | Humanized monoclonal antibody against the interleukin-6 receptor | Juvenile idiopathic arthritis, RA |
Rituximab (Rituxan® or MabThera®) | Chimeric anti-CD20 monoclonal antibody | RA, granulomatosis with polyangiitis (Wegener) |
Abatacept (Orencia®) | Fusion of extracellular domain of human CTLA-4 and the Fc domain of IgG | RA |
Alefacept (Amevive®) | Fusion of CD2-binding region of LFA-3 and the CH2 and CH3 domains of IgG1 | Psoriasis |
Anakinra (Kineret®) | Recombinant, non-glycosylated human IL-1 receptor antagonist | RA |